D. Drygin

发表

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

D. V. Von Hoff, Adam Siddiqui-Jain, J. Bliesath, 2012, Molecular Cancer Therapeutics.

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

R. Hannan, M. Bywater, E. Sanij, 2011, Cancer research.

CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2010, Cancer research.

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.

J. Zuber, M. Dawson, R. Pearson, 2017, Blood.

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Carleen Cullinane, Ricky W Johnstone, S. Lowe, 2012, Cancer cell.

RNA Polymerase I Transcription

R. Hannan, D. Drygin, 2014 .

Targeting RNA polymerase I transcription and the nucleolus for cancer therapy

R. Pearson, R. Hannan, D. Drygin, 2013, Expert opinion on therapeutic targets.

CELL BIOLOGY AND SIGNALING

V. P. Collins, Michael A. Koldobskiy, R. Spang, 2010 .

7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.

Adam Siddiqui-Jain, Diwata Macalino, Nicole Streiner, 2011, Bioorganic & medicinal chemistry letters.

How Ribosomal Proteins and rRNA Recognize One Another

E. Nikonowicz, Herren Wu, D. Drygin, 2000 .

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma

A. Blackburn, R. Hannan, K. Hannan, 2022, Investigational New Drugs.

Cancer-cell-secreted Extracellular Vesicles Suppress Insulin Secretion through miR-122 to Impair Systemic Glucose Homeostasis and Contribute to Tumour Growth

Dorothy D. Sears, Wenwan Zhong, D. Pizzo, 2022, Nature Cell Biology.

Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.

D. Ryckman, D. Drygin, M. Haddach, 2012, Journal of medicinal chemistry.

Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Journal of medicinal chemistry.

The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer.

I. Grummt, W. Rice, D. Drygin, 2010, Annual review of pharmacology and toxicology.

RNA Polymerase I Transcription

R. Hannan, D. Drygin, 2014 .

341 POSTER CX-5461, a novel, orally bioavailable selective small molecule inhibitor of RNA polymerase I transcription, induces autophagy and shows potent antitumor activity

J. Bliesath, Caroline B. Ho, K. Anderes, 2008 .

Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease

J. Bergh, J. Hartman, C. Allis, 2019, Nature Communications.

Therapeutics , Targets , and Chemical Biology CX-4945 , an Orally Bioavailable Selective Inhibitor of Protein Kinase CK 2 , Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Brien, Adam Siddiqui-Jain, J. Bliesath, 2010 .

Structure of the L1 protuberance in the ribosome

Anders Liljas, Natalia Nevskaya, M. Selmer, 2003, Nature Structural Biology.

Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Molecular and Cellular Biochemistry.

Preclinical Development CK 2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Ef fi cacy : Mechanistic Rationale for Drug Combination Therapy

D. V. Hoff, Adam Siddiqui-Jain, J. Bliesath, 2012 .

Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis.

Amy Lin, D. V. Von Hoff, Adam Siddiqui-Jain, 2009, Cancer research.

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling

K. Khanna, R. Pearson, G. McArthur, 2016, Oncotarget.

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer

R. Pearson, R. Hannan, L. Furic, 2016, Clinical Cancer Research.

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.

R. Pearson, G. McArthur, R. Johnstone, 2016, Cancer discovery.

Magnesium ions mediate contacts between phosphoryl oxygens at positions 2122 and 2176 of the 23S rRNA and ribosomal protein L1.

D. Drygin, R. Zimmermann, 2000, RNA.

Induction of toll-like receptors and NALP/PAN/PYPAF family members by modified oligonucleotides in lung epithelial carcinoma cells.

C. Bennett, D. Drygin, S. Koo, 2005, Oligonucleotides.

Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma

M. Bredel, Ying Zheng, S. Bellis, 2013, Clinical Cancer Research.

Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, Cancer letters.

CK2 as a Logical Target in Cancer Therapy: Potential for Combining CK2 Inhibitors with Various Classes of Cancer Therapeutic Agents

D. Drygin, 2013 .

Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2011, Biochemical and biophysical research communications.

Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.

Adam Siddiqui-Jain, Diwata Macalino, Nicole Streiner, 2012, Bioorganic & medicinal chemistry letters.

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia

J. Barata, M. G. Silva, D. Drygin, 2014, Leukemia.

Targeting the nucleolus for cancer-specific activation of p53.

D. V. Von Hoff, G. McArthur, R. Hannan, 2014, Drug discovery today.

Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells

F. Iorio, J. Saez-Rodriguez, P. Chakravarty, 2016, Oncotarget.

Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.

Adam Siddiqui-Jain, J. Bliesath, Diwata Macalino, 2012, ACS medicinal chemistry letters.

In Vitro and in Vivo Targeting of Chronic Lymphocytic Leukemia Using CX-4945, a Clinical-Stage CK2-Specific Inhibitor.

J. Barata, M. G. Silva, D. Drygin, 2012 .

Sequence-dependent cytotoxicity of second-generation oligonucleotides.

C. Bennett, D. Drygin, C Frank Bennett, 2004, Nucleic acids research.

Quarfloxin (CX-3543) disrupts the Nucleolin/ rDNA quadruplex complexes, inhibits the elongation by RNA Polymerase I and exhibits potent antitumor activity in models of cancer

S. O'Brien, W. Rice, D. Drygin, 2008 .

CX-4945, a Selective and Orally Bioavailable Inhibitor of Protein Kinase CK2 Inhibits PI3K/Akt, JAK-STAT and NF-κB Signaling and Induces Apoptosis In Multiple Myeloma Cells

Adam Siddiqui-Jain, J. Bliesath, Nicole Streiner, 2010 .

Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs.

Adam Siddiqui-Jain, Diwata Macalino, S. O'Brien, 2012, Bioorganic & medicinal chemistry letters.

Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment Studies

A. Blackburn, A. Loh, R. Hannan, 2023, Biomedicines.

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

S. Lowe, C. Schmitt, R. Pearson, 2012, Cancer cell.

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics.

Adam Siddiqui-Jain, J. Bliesath, M. Omori, 2012, ACS medicinal chemistry letters.

Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.

Adam Siddiqui-Jain, Diwata Macalino, Nicole Streiner, 2012, Bioorganic & medicinal chemistry letters.